Ezurpimtrostat is under clinical development by Genoscience Pharma and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ezurpimtrostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ezurpimtrostat overview
Ezurpimtrostat (GNS-561) is under development for the treatment of coronavirus disease 2019 (COVID-19), glioblastoma multiforme (GBM), gynaecological cancer, liver cancer, metastatic hepatocellular carcinoma and liver fibrosis. The drug candidate is administered orally as a capsule formulation and also as an intraarterial route (TACE). The drug candidate is a new chemical compound and is an autophagy inhibitor that targets and kill cancer stem cells (CSCs). It also acts by targeting transforming growth factor beta 1 (TGF-B1) and palmitoyl protein thioesterase (PPT-1).
It was under development for the treatment of bile duct cancer (cholangiocarcinoma), metastatic hepatocellular carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer
Genoscience Pharma overview
Genoscience Pharma (Genoscience) is a pharmaceutical company that develops new proprietary chemical compounds against cancer stem cells. The company discovers and develops novel therapeutic products for alternative treatment of acute myeloid leukemia and GNS561 to treat hepatocarcinoma. Its products portfolio comprise of BL-8030, GNS 396, GNS XXX and GNS 561. Genoscience’s product indicates therapy to Hepatitis C Virus infections; HCV protease inhibitor; anti CSC in acute myeloid leukemia; and anti CSC in hepatitis C cells. The company’s CSCs such as GNS396 and GNS561 could be combined with chemotherapy drugs to rise the remission time and reduce the relapse frequency in cancer patients. It collaborates with biotechnology companies to develop protease inhibitors and treatment of Hepatitis C. Genoscience is headquartered in Marseille, France.
For a complete picture of Ezurpimtrostat’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Ezurpimtrostat in Metastatic Hepatocellular Carcinoma (HCC)
Premium Insights
The gold standard of business intelligence.
